• Nordicus set a Phase IIa patient trial of periodontitis drug candidate QR-01 for H1 2027 at the University of Copenhagen.
• Preclinical results have already been presented internally, showing improved disease outcomes and reduced bone damage in animal models, without reported tolerability issues.
• Separately, an oral leukoplakia gel candidate, QR-02, is slated for a Phase IIa start in Europe in H1 2027, supported by a Danish regulator toxicity waiver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nordicus Partners Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606151336PRIMZONEFULLFEED9747170) on June 15, 2026, and is solely responsible for the information contained therein.